Luxeptinib

N/A

Report date: 2024/06/24 18:15:24

NMEFirst In Class

Base Information

Drug NameLuxeptinib

Drug Alias NameLUXCG-806CG’806CG-026806CG026806

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase Aurora inhibitorsTyrosine-protein kinase SRC inhibitorsMyc proto-oncogene protein inhibitors +[10]

TargetsMyc proto-oncogene proteinTyrosine-protein kinase SRCTyrosine-protein kinase BTK +[10]

Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma, Follicular +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCrystalgenomics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAptose Biosciences Inc

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse

Inactive IndicationsMyelodysplastic SyndromesLymphoma, Non-HodgkinLeukemia, Myeloid, Acute +[4]

Other Information

ATC CodeN/A